CTOs on the Move

Emerging Health Information Technology

www.emerginghealthit.com

 
Emerging Health Information Technology is a Yonkers, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Superior Prescriptions Pads

Superior Prescriptions Pads is a Santa Fe Springs, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Intelligent InSites

Intelligent InSites, Inc. is a leading provider of automation solutions that transform healthcare.

Alternate Health

Alternate Health (CSE: AHG, OTCQB: AHGIF) an international leader in the hemp-derived CBD industry, including extraction, product development and distribution. Alternate Health`s industry-leading software systems provide the platform for the company`s diverse operations, including blockchain tax collection systems, hemp-derived CBD product distribution, extract manufacturing and patient management systems for specialty clinics across North America. Through Alternate Health`s subsidiary, Blaine Labs, the Company is a leader in cGMP medical product manufacturing and distribution, with over 50 product SKUs available from major retailers, including Walmart, Amazon, CVS and Walgreens. Alternate Health`s corporate office is located in Toronto, Canada, with additional offices in Venice, California, and San Antonio, Texas. The Company is well positioned to reinvest internal operating cash flow in its platform and product development over the long term, creating an attractive investment profile for its shareholders.

Virginia Hospital

Virginia Hospital is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Bioatla

BioAtla was founded in 2007 and employs deep expertise in protein engineering to develop better monoclonal antibody and other protein therapeutics. Our suite of proprietary technologies (protected by more than 70 issued patents and patent applications) has enabled us to develop dozens of novel therapeutic proteins for our partners and our own pipeline. We accelerate the process from target discovery to manufacturing and preclinical studies by creating drugs with more selective targeting, greater affinity, and more cost-efficient and predictable manufacturing. In the process we also create valuable, protectable IP that gives our partners significant competitive advantage. The culmination of our protein evolution technologies is our Conditionally Active Biologics (CAB)platform. Monoclonal antibodies or enzymes can be engineered for selective conditional activation, i.e. the protein`s functions are designed to modulate with changes in microphysical conditions (e.g., pH level, oxidation, temperature, pressure concentration, presence of certain ions, hydrophobicity and competing protein binding). Tumors and other kinds of diseased tissue give rise to unique localized conditions distinct from normal tissue. CAB designed monoclonal antibodies can be programmed to deliver an ADC payload and/or recruit the immune response to specific sites and conditions in the body.